WO2006037994A3 - Methode - Google Patents

Methode Download PDF

Info

Publication number
WO2006037994A3
WO2006037994A3 PCT/GB2005/003814 GB2005003814W WO2006037994A3 WO 2006037994 A3 WO2006037994 A3 WO 2006037994A3 GB 2005003814 W GB2005003814 W GB 2005003814W WO 2006037994 A3 WO2006037994 A3 WO 2006037994A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb receptor
response
egfr mutations
mutations altering
egfr
Prior art date
Application number
PCT/GB2005/003814
Other languages
English (en)
Other versions
WO2006037994A2 (fr
Inventor
Gillian Ellison
Ruth Eleanor March
Alan Wookey
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Gillian Ellison
Ruth Eleanor March
Alan Wookey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0422158A external-priority patent/GB0422158D0/en
Priority claimed from GB0508493A external-priority patent/GB0508493D0/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Gillian Ellison, Ruth Eleanor March, Alan Wookey filed Critical Astrazeneca Ab
Publication of WO2006037994A2 publication Critical patent/WO2006037994A2/fr
Publication of WO2006037994A3 publication Critical patent/WO2006037994A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode permettant de prédire le degré de probabilité selon lequel un patient candidat à un traitement par médicament à récepteur erbB répondra audit traitement. Cette méthode consiste à déterminer la séquence du facteur EGFR (facteur de croissance épidermique) dans un échantillon de tumeur prélevé sur le patient afin de prédire un accroissement de la probabilité d'une réponse au médicament récepteur de EGFR. En particulier, l'invention porte sur la détermination de la séquence d'EGFR à l'une quelconque des positions suivantes telles que définies dans SEQ ID NO: 1: position 2308 correspondant à A; position 2348 correspondant à T; position 2588 correspondant à A; ou position 2689 correspondant à A; ou à l'une quelconque des positions suivantes telles que définies dans SEQ ID NO: 2: position 770 correspondant à l'aspargine; 783 à l'isoleucine; position 863 à l'acide aspartique; ou position 897 à l'isoleucine.
PCT/GB2005/003814 2004-10-06 2005-10-04 Methode WO2006037994A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0422158A GB0422158D0 (en) 2004-10-06 2004-10-06 Method
GB0422158.6 2004-10-06
GB0508493A GB0508493D0 (en) 2005-04-27 2005-04-27 Method
GB0508493.4 2005-04-27

Publications (2)

Publication Number Publication Date
WO2006037994A2 WO2006037994A2 (fr) 2006-04-13
WO2006037994A3 true WO2006037994A3 (fr) 2006-06-08

Family

ID=35453337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003814 WO2006037994A2 (fr) 2004-10-06 2005-10-04 Methode

Country Status (2)

Country Link
TW (1) TW200617396A (fr)
WO (1) WO2006037994A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506670D0 (en) * 2005-04-01 2005-05-11 Astrazeneca Ab Method
CN106755297A (zh) * 2016-11-15 2017-05-31 上海派森诺医学检验所有限公司 一组基于arms荧光定量pcr检测egfr基因t790m突变的引物组及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094357A2 (fr) * 2004-03-31 2005-10-13 The General Hospital Corporation Procede permettant de determiner la reponse d'un cancer a des traitements cibles par le recepteur du facteur de croissance epidermique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094357A2 (fr) * 2004-03-31 2005-10-13 The General Hospital Corporation Procede permettant de determiner la reponse d'un cancer a des traitements cibles par le recepteur du facteur de croissance epidermique

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
GAZDAR A F ET AL: "Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, vol. 10, no. 10, October 2004 (2004-10-01), pages 481 - 486, XP004586557, ISSN: 1471-4914 *
HUANG SHIU-FENG ET AL: "High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 DEC 2004, vol. 10, no. 24, 15 December 2004 (2004-12-15), pages 8195 - 8203, XP002369911, ISSN: 1078-0432 *
KOSAKA TAKAYUKI ET AL: "Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.", CANCER RESEARCH. 15 DEC 2004, vol. 64, no. 24, 15 December 2004 (2004-12-15), pages 8919 - 8923, XP002369912, ISSN: 0008-5472 *
LYNCH THOMAS J ET AL: "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.", THE NEW ENGLAND JOURNAL OF MEDICINE. 20 MAY 2004, vol. 350, no. 21, 20 May 2004 (2004-05-20), pages 2129 - 2139, XP002359960, ISSN: 1533-4406 *
MARCHETTI ANTONIO ET AL: "EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 1 FEB 2005, vol. 23, no. 4, 1 February 2005 (2005-02-01), pages 857 - 865, XP002369910, ISSN: 0732-183X *
PAEZ J GUILLERMO ET AL: "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.", SCIENCE. 4 JUN 2004, vol. 304, no. 5676, 4 June 2004 (2004-06-04), pages 1497 - 1500, XP002359959, ISSN: 1095-9203 *
PAO W ET AL: "EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 36, 7 September 2004 (2004-09-07), pages 13306 - 13311, XP002334314, ISSN: 0027-8424 *
PAO WILLIAM ET AL: "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.", PLOS MEDICINE / PUBLIC LIBRARY OF SCIENCE. MAR 2005, vol. 2, no. 3, March 2005 (2005-03-01), pages e73, XP002359961, ISSN: 1549-1676 *
ROSELL ET AL: "Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 50, no. 1, October 2005 (2005-10-01), pages 25 - 33, XP005106172, ISSN: 0169-5002 *
TARON MIGUEL ET AL: "Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 AUG 2005, vol. 11, no. 16, 15 August 2005 (2005-08-15), pages 5878 - 5885, XP002369908, ISSN: 1078-0432 *
TOKUMO MASAKI ET AL: "The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 FEB 2005, vol. 11, no. 3, 1 February 2005 (2005-02-01), pages 1167 - 1173, XP002369909, ISSN: 1078-0432 *
TOMIZAWA YOSHIO ET AL: "Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 OCT 2005, vol. 11, no. 19 Pt 1, 1 October 2005 (2005-10-01), pages 6816 - 6822, XP002369907, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2006037994A2 (fr) 2006-04-13
TW200617396A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
NL301089I2 (nl) imlifidase
WO2008088854A3 (fr) Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie
WO2005056606A3 (fr) Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2004071572A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
WO2003085095A3 (fr) Nouveaux genes exprimes
WO2004074455A3 (fr) Variants de la region fc
IL176674A0 (en) Fc region variants
EP2479284A3 (fr) Procédés et réactifs pour le traitement et le diagnostic des troubles vasculaires et la dégénération maculaire liée à l'âge
WO2004111273A3 (fr) Marqueurs d'expression genique utilises en vue d'une reaction a des medicaments inhibiteurs de egfr
WO2008151803A3 (fr) Nouveaux polymorphismes du gène abcb1 associés à une absence de réaction clinique à des médicaments
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2006081311A3 (fr) Compositions et methodes de disruption intracellulaire de vegf et de vegfr-2 a l'aide de recepteurs intracellulaires
WO2003013533A3 (fr) Moyens et procedes ameliorant le traitement du cancer sur la base de mrp1
BRPI0819018A2 (pt) "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf"
WO2009087462A3 (fr) Récepteur à éphrine de type a
WO2006078853A3 (fr) Proteine d'interaction avec la thioredoxine (txnip) en tant que regulateur de la fonction vasculaire
WO2004081043A3 (fr) Variants de baff et leurs methodes d'utilisation
WO2006037994A3 (fr) Methode
WO2005112568A3 (fr) Marqueurs haplotypes et procedes d'utilisation de ceux-ci pour determiner la reponse a un traitement
WO2005007871A3 (fr) Marqueur genetique de reponse a des antipsychotiques atypiques et a des antidepresseurs et leurs methodes d'utilisation
DE602005016290D1 (de) Glichkeit
WO2007131133A3 (fr) Procédés et compositions se rapportant aux polypeptides zpa
WO2003055980A3 (fr) Molecules du type il-17 et utilisations associees
WO2008052016A3 (fr) Récepteur associé à la sortiline sorl1 présentant un lien fonctionnel et génétique avec la maladie d'alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase